Pfizer And Valneva's Lyme Disease Vaccine Candidate PF-07307405 Clears EMA Validation Of Marketing Authorization Application After Phase 3 VALOR Trial Showed More Than 70% Efficacy
Share
Why It Matters
Pfizer and Valneva's new Lyme disease vaccine passed an important European safety check and showed it works well in testing. When a medicine passes these big hurdles, it's a sign the company did something right, though the vaccine still needs final approval before people can use it.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.